Tinghua Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Tinghua Li has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Min Li
Department of Laboratory Medicine, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
2 shared publications Bingchao Cai
Department of Infection Control, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, China
1 shared publicationDawei Li
Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, China
1 shared publicationFeng Lu
Department of Infection Control, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, China
1 shared publicationGuoxiu Xiang
Department of Laboratory Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University
1 shared publicationHaihui Yang
Department of Laboratory Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University
1 shared publication
Latest Publications
- 26 October 2025
- Published by Elsevier in American Journal of Infection Control
- Vol. 54 (4) , 396-401
The neglected 4th catheter: An suspected outbreak of carbapenem-resistant Pseudomonas aeruginosa in a kidney transplant ward
- 26 October 2025
- Published by Elsevier in American Journal of Infection Control
- Vol. 54 (4) , 396-401
The neglected 4th catheter: An suspected outbreak of carbapenem-resistant Pseudomonas aeruginosa in a kidney transplant ward
- Open Access
- 31 January 2025
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 69 (1) , e0123524
Adaptive evolution of extensive drug resistance and persistence in epidemic ST11 KPC-producing Klebsiella pneumoniae during antimicrobial chemotherapy
The global rise of carbapenem-resistant Klebsiella pneumoniae , including strains producing K. pneumoniae carbapenemase (KPC) types, poses a significant public health challenge due to their resistance to critical antibiotics. Treatment options for infections caused by KPC-producing K. pneumoniae (KPC-KP) are increasingly limited, particularly as these strains develop resistance to last-line antibiotics such as ceftazidime/avibactam and colistin. This study investigates the evolution of antibiotic resistance and persistence in a series of clonally related ST11 KPC-KP strains isolated from a single patient undergoing extended antimicrobial treatment. The patient, a 47-year-old male with a history of kidney transplantation, developed multiple KPC-KP lung infections during his hospital stay. Resistance to colistin and ceftazidime/avibactam emerged during treatment with these antibiotics. Key resistance mechanisms identified included the integration of IS Kpn26 into mgrB gene, leading to mgrB inactivation and colistin resistance, and the emergence of novel bla KPC-2 variants ( bla KPC-71 and bla KPC-179 ) that confer resistance to ceftazidime/avibactam. Despite the development of colistin resistance in a ceftazidime/avibactam-resistant KPC-KP strain following combination therapy, the patient’s clinical condition significantly improved. Phenotypic assays showed that mgrB disruption in KPC-KP resulted in increased biofilm formation and higher susceptibility to phagocytosis. In mouse models, KPC-KP strains with mgrB disruption showed reduced virulence, increased lung colonization and persistence, and a lower inflammatory response, suggesting that mgrB disruption facilitates the transition from acute infection to colonization. This study highlights the complex interplay between antibiotic resistance and bacterial fitness, offering insights into why some patients experience clinical improvement despite severe drug resistance and incomplete bacterial clearance.
- 31 January 2025
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 69 (1) , e0123524
Open AccessAdaptive evolution of extensive drug resistance and persistence in epidemic ST11 KPC-producing Klebsiella pneumoniae during antimicrobial chemotherapy
The global rise of carbapenem-resistant Klebsiella pneumoniae , including strains producing K. pneumoniae carbapenemase (KPC) types, poses a significant public health challenge due to their resistance to critical antibiotics. Treatment options for infections caused by KPC-producing K. pneumoniae (KPC-KP) are increasingly limited, particularly as these strains develop resistance to last-line antibiotics such as ceftazidime/avibactam and colistin. This study investigates the evolution of antibiotic resistance and persistence in a series of clonally related ST11 KPC-KP strains isolated from a single patient undergoing extended antimicrobial treatment. The patient, a 47-year-old male with a history of kidney transplantation, developed multiple KPC-KP lung infections during his hospital stay. Resistance to colistin and ceftazidime/avibactam emerged during treatment with these antibiotics. Key resistance mechanisms identified included the integration of IS Kpn26 into mgrB gene, leading to mgrB inactivation and colistin resistance, and the emergence of novel bla KPC-2 variants ( bla KPC-71 and bla KPC-179 ) that confer resistance to ceftazidime/avibactam. Despite the development of colistin resistance in a ceftazidime/avibactam-resistant KPC-KP strain following combination therapy, the patient’s clinical condition significantly improved. Phenotypic assays showed that mgrB disruption in KPC-KP resulted in increased biofilm formation and higher susceptibility to phagocytosis. In mouse models, KPC-KP strains with mgrB disruption showed reduced virulence, increased lung colonization and persistence, and a lower inflammatory response, suggesting that mgrB disruption facilitates the transition from acute infection to colonization. This study highlights the complex interplay between antibiotic resistance and bacterial fitness, offering insights into why some patients experience clinical improvement despite severe drug resistance and incomplete bacterial clearance.